Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Wegovy Side Effects: What Is Common and What Is Rare

Wegovy side effects are mostly gut problems: nausea, diarrhea, vomiting, constipation and belly pain top the label's list. Many people on placebo, a dummy treatment, reported the same things, so the trials compare the gap between the two groups. The serious risks sit in a separate list of label warnings.

The safety numbers come from the US prescribing information and Medication Guide (the June 2026 revision), checked again on 20 November 2026. Approval dates come from Drugs@FDA, and trial records from ClinicalTrials.gov. They are group results from trials, not a forecast for any one person. What the drug is and how it works is on our what is Wegovy page.

On this page

Wegovy side effects at a glance

Wegovy is semaglutide, a lab-made version of GLP-1, a hormone that helps regulate appetite; 94% of its sequence matches. The shot won FDA approval on 4 June 2021, and the pill followed on 22 December 2025. One label now covers both forms.

Wegovy side effect basics, from the US label revised June 2026 and Drugs@FDA, checked November 2026.
PointWhat the label says
What Wegovy isSemaglutide, a lab-made version of GLP-1, sold by prescription as a shot and as a pill
Label used hereUS prescribing information and Medication Guide, revised June 2026
Most common side effectNausea: 44 in 100 adults on Wegovy vs 16 in 100 on placebo (Table 3)
Any gut side effect73% on Wegovy vs 47% on placebo (section 6.1)
Stopped for good over side effects6.8% on Wegovy vs 3.2% on placebo (section 6.1)
Boxed warningThyroid C-cell tumors in mice and rats; unknown in humans (boxed warning, section 5.1)

With a lower calorie diet and more activity, the shot is approved for losing weight and keeping it off in two groups: people 12 and up who have obesity, and adults carrying extra weight who also have a health problem linked to it. Another approved use is cutting the chance of a heart attack, a stroke or death from heart disease, for adults whose established heart disease comes with obesity or overweight. MASH, a liver disease, is covered too, under accelerated approval: only adults without cirrhosis whose liver scarring is moderate to advanced. Accelerated means continued approval may depend on a confirming trial.

Sources: Wegovy prescribing information, DailyMed (revised June 2026); DailyMed label versions for Wegovy; Wegovy approvals, Drugs@FDA via openFDA

What are the common Wegovy side effects?

The gut list leads, by a wide margin. The label pools three placebo-controlled weight trials lasting up to 68 weeks: 2,116 adults got Wegovy and 1,261 got placebo. The table below sorts each side effect by its gap, the extra people out of 100 on Wegovy compared with placebo. The gap shows how far apart the two groups ended up, which a raw rate on its own hides.

Label Table 3, adults, percent reporting each side effect. Gap is our subtraction, Wegovy minus placebo. The low blood sugar row comes from the type 2 diabetes trial only.
Side effectWegovyPlaceboGap per 100
Nausea441628
Vomiting24618
Diarrhea301614
Constipation241113
Belly (abdominal) pain201010
Belching7under 1over 6
Tiredness1156
Indigestion936
Headache14104
Dizziness844
Low blood sugar, type 2 diabetes trial only624
Gastritis413
Bloating752
Gas642
Stomach flu (gastroenteritis)642
Reflux532
Hair loss312
Viral stomach flu431
Tingling or burning skin (dysesthesia)211

Sorted this way, nausea and vomiting stand out. Diarrhea looks big as a raw rate, but placebo had 16 in 100 too. Headache shows the opposite trap: 14 in 100 sounds high until you see 10 in 100 on placebo.

Counting every gut complaint together, label section 6.1 says 73% of adults on Wegovy reported at least one, and so did 47% on placebo. The label says these reactions came up most often in the step-up period at the start. Over the trials, 6.8% on Wegovy and 3.2% on placebo quit for good because of side effects. The top reasons were nausea (1.8% vs 0.2%), vomiting (1.2% vs 0%) and diarrhea (0.7% vs 0.1%).

The tingling or burning skin row covers several odd skin feelings. The label says they became more common as drug levels in the blood went up. Our Wegovy diarrhea guide goes deeper on that one symptom, and the GLP-1 side effects guide covers the drug class as a whole.

Sources: Wegovy prescribing information, DailyMed (revised June 2026); STEP 1 trial record (NCT03548935); STEP 2 trial record (NCT03552757); STEP 3 trial record (NCT03611582)

Why does Wegovy upset the gut?

The label offers two clues but no verdict. First, the stomach: semaglutide slows how fast the stomach empties, a bit like a sink with a slow drain. Second, the brain: the GLP-1 receptor also appears in appetite-related regions of the brain. Animal studies showed semaglutide reaching those regions and activating nerve cells that help control eating.

The label also says semaglutide lowers how much people eat, likely by acting on appetite. It never says that either the slow stomach or the brain effect causes the nausea, so neither should be read as the proven reason.

Sources: Wegovy prescribing information, DailyMed (revised June 2026)

What are the serious Wegovy side effects and warnings?

These are the label's warnings. Some have trial rates or counts, and some are known only from reports collected after approval, with no rate. The last column says which, and names the label section.

Warnings and precautions from the Wegovy label, adults on the shot vs placebo unless stated; the last column names the label section for each row.
RiskWhat the label reportsKind of data
Pancreatitis (swollen pancreas)Confirmed in 4 adults on Wegovy and 1 on placebo in the weight trials (0.2 vs under 0.1 cases per 100 patient years)Trial count, section 6.1
Gallstones1.6% on Wegovy vs 0.7% on placeboTrial rate, section 5.3
Gallbladder inflammation0.6% vs 0.2%; sudden gallbladder disease stayed more common even after weight loss was accounted forTrial rate, section 5.3
Severe gut reactions4.1% vs 0.9%; not recommended with severe gastroparesisTrial rate, section 5.6
Kidney injury7 adults on Wegovy vs 4 on placebo in the weight trials; since approval, reports of cases needing dialysis, mostly after fluid loss from nausea, vomiting or diarrheaTrial count (section 6.1) and reports (section 5.5)
Low blood sugar, type 2 diabetesClinically significant episodes in 6.2% vs 2.5%; higher with insulin or a sulfonylurea, another type of diabetes medicineTrial rate, section 5.4
Eye problems, type 2 diabetesRetinal disorders in 6.9% vs 4.2% in one trialTrial rate, section 6.1 (warning 5.8)
Faster heart rateResting rate up 1 to 4 beats a minute on average; a jump of 20 or more at any visit in 26% vs 16%Trial rate, section 5.9
Serious allergic reactionsAnaphylaxis and angioedema have been reportedReports, section 5.7
Stomach contents reaching the lungsRare reports under general anesthesia or deep sedation, across GLP-1 drugsRare reports, section 5.10

The aspiration warning ties back to the slow stomach. Food still in the stomach can reach the lungs under anesthesia. So the label asks patients to tell providers before a planned surgery or procedure. It adds that the data are too thin to say how to lower that risk.

The list has changed lately. The severe gut reactions warning has been in the label since at least November 2024, and its recent changes list shows that warning updated in October 2025. A suicidal behavior warning was removed in February 2026. The large SELECT heart trial logged only serious events and a few chosen types. In it, 16% on Wegovy and 8% on placebo stopped the study drug over an adverse event, meaning any health problem logged in the trial.

Sources: Wegovy prescribing information, DailyMed (revised June 2026); SELECT heart outcomes trial record (NCT03574597)

What is the Wegovy thyroid boxed warning?

It rests on rodents. In two-year studies, mice and rats given semaglutide developed thyroid C-cell tumors, and the tumors rose with higher exposure and longer treatment. The label says the meaning for humans has not been determined, and it is unknown whether Wegovy causes these tumors in people. In standard gene-damage tests, semaglutide did not damage DNA.

The label rules Wegovy out for people whose own history, or whose family's, includes medullary thyroid cancer. It also rules it out with MEN 2, a rare inherited gland condition. The Medication Guide lists a lump or swelling in the neck, hoarseness, trouble swallowing and shortness of breath as possible thyroid signs to tell a healthcare provider about.

Sources: Wegovy prescribing information, DailyMed (revised June 2026); Wegovy Medication Guide, DailyMed (revised June 2026)

When does the Wegovy label say to call a provider?

The Medication Guide names the signs for each serious side effect. The table repeats its wording in short form; it is the label speaking, not our advice.

Signs and actions as written in the Wegovy Medication Guide, revised June 2026.
Signs the guide listsWhat the guide says
Stomach pain that is severe and does not go away, whether or not there is nausea or vomiting; it may spread to the backPancreatitis: stop using Wegovy and call a healthcare provider right away
Pain in the upper stomach, yellow skin or eyes, fever, clay-colored stoolsGallbladder problems: call a healthcare provider
A swollen face, lips, tongue or throat; trouble breathing or swallowing; a severe rash or itching; feeling faint or dizzy; a very rapid heartbeatSerious allergic reaction: stop using Wegovy and get medical help right away
A lump or swelling in the neck, hoarseness, trouble swallowing, shortness of breathPossible thyroid signs: tell a healthcare provider
Changes in vision, in people with type 2 diabetesTell a healthcare provider

The guide ends its list by saying these are not all the possible side effects. It asks people to talk to a healthcare provider about any side effect that bothers them or lasts.

Sources: Wegovy Medication Guide, DailyMed (revised June 2026)

Are side effects different for the pill or for teens?

For the pill, label section 6.1 says the common side effects in its trial were similar in type and frequency to those in Table 3. Two warnings were measured on their own: severe gut reactions in 2% on the pill against 0% on placebo (section 5.6), and gallstones in 2.5% against 1% (section 5.3). The pill is approved for fewer uses than the shot, with no teen or MASH approval. How the pill gets past the stomach is on our Wegovy ingredients page.

For teens 12 and up, one 68-week trial in label Table 5 showed a similar pattern with more vomiting: nausea 42% against 18%, and vomiting 36% against 10%. Teens also had more gallstones, gallbladder inflammation, low blood pressure, rash and hives than adults. If you are comparing Wegovy with its sister brand, see is Wegovy the same as Ozempic.

Sources: Wegovy prescribing information, DailyMed (revised June 2026)

What else do people ask about Wegovy side effects?

What is the most common Wegovy side effect?+

Nausea. In the three placebo-controlled weight trials pooled in label Table 3, 44% of adults on Wegovy reported it, against 16% on placebo. Diarrhea, vomiting, constipation and belly pain came next.

Are Wegovy side effects worse at the start?+

The label says the gut reactions were reported most often during the step-up period at the start of treatment. It does not give a timeline for when they ease.

Does Wegovy cause hair loss?+

Hair loss is on the list in label Table 3: 3% of adults on Wegovy reported it in the weight trials, against 1% on placebo.

Does Wegovy cause thyroid cancer?+

Nobody knows for people. Mice and rats given semaglutide for two years developed thyroid C-cell tumors, and the label says it is unknown whether Wegovy causes them in humans. The boxed warning rests on that animal data.

Does the Wegovy pill have the same side effects as the shot?+

Mostly. Label section 6.1 says the common side effects in the pill trial were similar in type and rate to the shot table. Severe gut reactions were 2% on the pill against 0% on placebo (section 5.6), and gallstones 2.5% against 1% (section 5.3).

What are the serious Wegovy side effects?+

The label warns about pancreatitis, gallbladder disease, severe gut reactions, kidney injury, low blood sugar and eye problems in people with type 2 diabetes, a faster heart rate, serious allergic reactions, and food in the lungs under anesthesia. Some have trial rates and others come only from reports after approval.

Do teens get different side effects?+

The pattern was similar in the one trial of ages 12 and up, but vomiting was higher: 36% on Wegovy against 10% on placebo, in label Table 5. Teens also had more gallstones, gallbladder inflammation, low blood pressure, rash and hives than adults.

Sources: Wegovy prescribing information, DailyMed (revised June 2026); Wegovy Medication Guide, DailyMed (revised June 2026)

What did we learn about Wegovy side effects?

The takeaway: the common side effects sit in the gut, with placebo often close behind, so the gap between groups matters more than the raw rate. The label warnings cover the pancreas, gallbladder and kidneys, among others, and the thyroid finding comes from rodents with unknown meaning for people.

Trial numbers describe groups under trial conditions. The label itself says they cannot be compared directly with other drugs' trials and may not match what happens in everyday use. This page follows the June 2026 label, Drugs@FDA and the ClinicalTrials.gov records, all read in November 2026.

We re-check label pages as set out in our medical review policy. Spotted a wrong number? Report it through our corrections policy.

Sources: Wegovy prescribing information, DailyMed (revised June 2026); Wegovy approvals, Drugs@FDA via openFDA

This page reports what the Wegovy label says and gives no advice. It is not a reason to start, stop or change a medicine, so take any symptom or health question to a licensed clinician.

Sources

  1. 1.Wegovy prescribing information, Novo Nordisk, on DailyMed, revised June 2026 (SPL version 19, read 20 November 2026): approved uses and the MASH accelerated approval; semaglutide has 94% sequence homology to human GLP-1; Table 3 adverse reactions from 3 placebo-controlled trials (2,116 adults on Wegovy, 1,261 on placebo, up to 68 weeks); gut reactions in 73% vs 47% and most often during the step-up period; 6.8% vs 3.2% stopped for good over side effects; warnings for pancreatitis, gallbladder disease, severe gut reactions, kidney injury, low blood sugar in type 2 diabetes, eye problems in type 2 diabetes, heart rate, allergic reactions and aspiration under anesthesia; the boxed warning on rodent thyroid C-cell tumors; the teen table; the tablet trial; Recent Major Changes; delayed stomach emptying and lower calorie intake in section 12.
  2. 2.Wegovy Medication Guide, revised June 2026, in the same DailyMed label: the thyroid warning signs, the serious side effect list with when to call a healthcare provider, and the note that these are not all the possible side effects.
  3. 3.DailyMed label versions for Wegovy, read 19 November 2026: version 19, published 30 June 2026, covers the Wegovy shot and tablets in one document.
  4. 4.Drugs@FDA records via openFDA, read 19 November 2026: Wegovy shot first approved 4 June 2021 (NDA 215256); Wegovy tablets approved 22 December 2025 (NDA 218316).
  5. 5.ClinicalTrials.gov, STEP 1 (NCT03548935): adults with overweight or obesity. Matched to the label study by enrollment (1,961).
  6. 6.ClinicalTrials.gov, STEP 2 (NCT03552757): adults with overweight or obesity and type 2 diabetes. Source of the low blood sugar and eye rows.
  7. 7.ClinicalTrials.gov, STEP 3 (NCT03611582): adults with overweight or obesity, with an intensive lifestyle program.
  8. 8.ClinicalTrials.gov, SELECT (NCT03574597): heart outcomes trial of 17,604 adults; collected only serious events, events leading to stopping and events of special interest; 16% on Wegovy vs 8% on placebo stopped the study drug over an adverse event.